UROLOGY is a prestigious journal published by Elsevier Science Inc, renowned for disseminating high-quality research and reviews in the field of urology. With an ISSN of 0090-4295 and E-ISSN 1527-9995, this journal has been a trusted resource since its inception in 1973 and continues to provide insights into the latest advancements and clinical practices in urology, maintaining a category quartile of Q2 as of 2023. The journal ranks 50th out of 120 in the Scopus metrics for Medicine - Urology, placing it in the 58th percentile, which underscores its influence and relevance in the academic community. Although it is not structured as an open access journal, it offers a wealth of knowledge vital for researchers, healthcare professionals, and students alike, enabling them to stay abreast of evolving treatments and innovations in the field. As we move towards 2024, UROLOGY remains committed to advancing research and enhancing practices in urological care, fostering a collaborative environment among its readership.

Prostate Cancer is a leading peer-reviewed Open Access journal published by HINDAWI LTD, dedicated to advancing the field of urology and oncology through high-quality research and innovative studies. Established in 2011, this journal serves as a vital platform for disseminating findings related to prostate cancer diagnostics, treatment strategies, and patient care, striving to collaborate and connect researchers from around the globe. With an impact factor reflective of its critical input in the scientific community, the journal showcases compelling manuscripts, reviews, and case reports that are accessible to a wide audience given its open access policy. Located in London, England, Prostate Cancer has made significant strides in its category quartiles, achieving Q4 in Cancer Research and Q3 in both Oncology and Urology as of 2023, reflecting its growing relevance and readership. With Scopus rankings indicating its position within the broader medical fields, the journal is a valuable resource for researchers, professionals, and students alike, contributing to the collective effort to improve outcomes in prostate cancer research and treatment.

Frontiers in Cardiovascular Medicine is a leading open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing research in the field of cardiology and cardiovascular medicine. Since its inception in 2014, the journal has become a vital platform for the dissemination of high-quality research, boasting a commendable Q2 rank in the 2023 category for Cardiology and Cardiovascular Medicine. With a focus on promoting innovative studies and clinical insights, Frontiers in Cardiovascular Medicine facilitates open access to its content, allowing researchers, healthcare professionals, and students from around the globe to engage with the latest findings which are critical for the advancement of cardiovascular health. The journal's significant presence in the academic landscape, as indicated by its Scopus ranking (161/387 and 58th percentile), underscores its importance as a research outlet in this essential field. Located in Lausanne, Switzerland, the journal continues to support the global cardiovascular community by encouraging collaboration and knowledge sharing to address the challenges faced in cardiovascular medicine today.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.

BMC Urology is a premier open-access journal dedicated to advancing research in the field of urology, reproductive medicine, and miscellaneous aspects of medicine. Published by BMC since 2001 and based in the United Kingdom, this journal provides a platform for researchers, clinicians, and students to disseminate their findings and explore the latest innovations and advancements within these vital fields. With a notable impact factor and categorization in the Q2 quartile for various categories of medicine, BMC Urology stands as a reputable source, ranking 51st out of 120 in Urology and 44th out of 90 in Reproductive Medicine according to Scopus metrics. The journal fosters knowledge sharing through its open-access model, ensuring that research is accessible to all. As it converges from 2001 to 2024, BMC Urology continues to play a crucial role in shaping the landscape of urological research and providing invaluable insights into clinical practices.

African Journal of Urology (ISSN: 1110-5704, E-ISSN: 1961-9987) is a leading scholarly publication in the field of urology, published by SPRINGER from the United Kingdom. Since adopting an open access model in 2012, this journal has aimed to increase the visibility and dissemination of vital research findings across the African continent and beyond. With a current impact factor and significant standing, as denoted by its Q3 ranking in Urology for 2023, it serves as an essential platform for clinicians, researchers, and students alike. The journal's scope encapsulates all aspects of urology, fostering advancements in both clinical practices and innovative research while specifically addressing healthcare challenges relevant to African populations. As part of its commitment to accessibility and academic excellence, the journal offers full open access to its content, allowing for a broad readership and engagement with cutting-edge studies. Engage with the African Journal of Urology to contribute to and stay informed about vital developments in urological science.